The presence of N-nitroso compounds, particularly N-nitrosamines, in pharmaceutical products has raised global safety concerns due to their significant genotoxic and mutagenic effects. This systematic review investigates their toxicity in active pharmaceutical ingredients (APIs), drug products, and pharmaceutical excipients, along with novel analytical strategies for detection, root cause analysis, reformulation strategies, and regulatory guidelines for nitrosamines. This review emphasizes the molecular toxicity of N-nitroso compounds, focusing on genotoxic, mutagenic, carcinogenic, and other physiological effects. Additionally, it addresses the ongoing nitrosamine crisis, the development of nitrosamine-free products, and the importance of sensitive detection methods and precise risk evaluation. This comprehensive overview will aid molecular biologists, analytical scientists, formulation scientists in research and development sector, and researchers involved in management of nitrosamine-induced toxicity and promoting safer pharmaceutical products.
1 January 2020 in Research Journal of Pharmacy and Technology
The measurement of teneligliptin in a drug pure in compliance with the ICH Guidelines, an easy and extraction free UV spectrophotometric method, was developed and validated. At 246nm and linearity of concentration of 10–50μg/ml, the drug shows strong absorption. The process for relaying the drug reaction to MeOH was calculated by its absorption maximum (λmax) 246nm in order to achieve a colorless solution. In the 10–50μg/ml concentration range, the rule on beer complied. The calibration chart was found to be linear, and the coefficient of correlation (r2) was found to be 0.9952%. The experimental value LOD and LOQ parameters for the proposed procedure are measured, respectively, like 2.25 and 6.83μg/mL. Teneligliptin recovery was reported as 101.58%. To maximize the reaction condition, all of the parameters were analyzed.
A Specific, Linear and Precise reversed phase- HPLC was developed for the simultaneous estimation of Metformin HCl and Empagliflozin and the column used is Zorbax SB Phenyl with length, Internal diameter and Particle size of 250mm, 4.6 mm and 5µm respectively. The Mobile phase is Phosphate buffer: ACN: Methanol in ratio 45:25:30. 1.0 ml/min was the used flow rate and the wavelength was adjusted to 220nm for detection. The retention time for Empagliflozin was found to be 5.5min and for Metformin was 9.3min. Both the APIs exhibited good linearity revealing correlation coefficient(R) of 0.9999. The percentage recoveries for Metformin and Empagliflozin was found to be 100.0 – 100.9% and 100.3 – 102.4% respectively which was found to be within the limit. Forced degradation studies were performed and the developed method has suitable specificity as no interference is observed with impurity spiked sample and placebo of Drug Product. The proposed drug products were subjected to various types of stress conditions according to ICH Q1 guidelines like acidic, alkaline, neutral, peroxide, and Thermal conditions. The degradation products were well resolved from the main peaks , thus indicating the stability- indicating nature of the method. The method was validated with respect to system suitability, linearity, accuracy, precision and robustness according to ICH guidelines and the proposed RP-HPLC Method was accurate, precise and linear for the simultaneous determination of Metformin and Empagliflozin in bulk and pharmaceutical formulations.